Inny tytuł:

Gene therapy of cardiovascular diseases

Wydawca:

Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS

Abstrakt:

Despite progress in pharmacotherapy, there is still a lack of efficient treatment of advanced stages of cardiovascular diseases. Therefore, great expectations are connected with gene therapy. First clinical experiments of gene transfer of vascular endothelial growth factor (VEGF) were carried out in 1994-1998 on patients with critical leg ischemia. They resulted in the improvement of vascularisation and prevented the amputation of the limbs. Promising results have been also obtained with DNA decoys binding the EF2 transcription factor. In this way, the expression of genes enhancing the proliferation of vascular smooth muscle cells have been inhibited and in consequence the narrowing of the lumen of arterio-venous bypasses have been inhibited.

Czasopismo/Seria/cykl:

Biotechnologia, vol.66, 3 (2004)-.

Tom:

66

Zeszyt:

3

Strona pocz.:

35

Strona końc.:

54

Szczegółowy typ zasobu:

Article

Format:

application/pdf ; application/pdf

Identyfikator zasobu:

0860-7796 ; oai:rcin.org.pl:113846

Źródło:

Library of Institute of Bioorganic Chemistry PAS

Język:

pol

Język streszczenia:

eng

Zakres czasowy:

1988-2010

Prawa:

Creative Commons Attribution BY-SA 4.0 license

Zasady wykorzystania:

Copyright-protected material. [CC BY-SA 4.0] May be used within the scope specified in Creative Commons Attribution BY-SA 4.0 license, full text available at:

Digitalizacja:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Lokalizacja oryginału:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Dofinansowane ze środków:

Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.

Dostęp:

Open